CAR T cell therapy redirects patient T cells to target and eliminate tumor cells. CARs, fusion proteins with antibody-derived antigen recognition and T cell signaling domains, gained FDA approval in 2017 for CD19-targeted therapies in B-cell malignancies. Lentiviral vectors are crucial for CAR transduction in T cell manufacturing, offering stable integration and efficient transduction of dividing/nondividing cells. Creative Biogene provides a comprehensive line of CAR-T lentiviral particles, delivering ready-to-transduce CAR-T lentiviruses with up to 10^9 IFU/mL for accelerated research timelines. For custom lentiviral packaging service, please feel free to contact us.